Modern Healthcare (4/5, Gillespie, Subscription Publication) reports the proliferation in “investor-owned or independently owned stand-alone clinics” offering ketamine, an off-label treatment for depression, “is concerning to many in the drug safety and mental health fields.” Off-label use of ketamine offers “no regulatory oversight of doctors’ prescribing patterns, safety protocols or adverse events in patients.” In addition, ketamine “is sometimes marketed for a host of other chronic diseases and behavioral diagnoses that have little scientific backing.”
Related Links:
— “Modern Healthcare (Requires Subscription)